A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Therapeutic Use
- Acronyms ADAPT
- Sponsors Janssen
- 24 Aug 2017 Planned End Date changed from 1 Aug 2019 to 6 Aug 2030.
- 24 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 6 Aug 2019.
- 25 Feb 2016 Treatment table revised to include only one maintenance dose instead of two maintenance doses.